---
aliases: [NVO]
---
#actor #pharma #glp1 #denmark #public

**Novo Nordisk** — GLP-1 leader. Ozempic, Wegovy. $33B semaglutide run-rate. Stock -50% in 2025 on growth concerns.

---

## Why Novo Nordisk matters

| Metric | Value |
|--------|-------|
| Ticker | NVO (NYSE), NOVO-B (Copenhagen) |
| Semaglutide revenue | **~$33B** (2025 run-rate) |
| GLP-1 market share | 68% (international) |
| Stock 2025 | **-50%** (worst year on record) |

---

## Key products

| Product | Indication | Q3 2025 Revenue |
|---------|------------|-----------------|
| **Ozempic** | Diabetes | $4.7B (+3% YoY) |
| **Wegovy** | Obesity | DKK 20B (+168% YoY) |
| Rybelsus | Diabetes (oral) | ~$1.7B |

**Semaglutide franchise:** H1 2025 sales ~$16.4B, annualized ~$33B.

---

## Growth deceleration

| Metric | Q2 2025 | Q3 2025 |
|--------|---------|---------|
| Ozempic growth | +15% YoY | **+3% YoY** |
| Wegovy growth | +67% YoY | **+18% YoY** |

**Guidance cuts:** Three times in 2025, now expecting 8-11% sales growth (was 14%+).

---

## Competitive pressure

| Competitor | US GLP-1 Share |
|------------|----------------|
| **Eli Lilly** | **58%** |
| Novo Nordisk | 42% |

Lilly's Mounjaro/Zepbound gaining share rapidly.

---

## Pipeline & catalysts

| Product | Status |
|---------|--------|
| Oral Wegovy | US launch **Jan 2026** |
| CagriSema | Phase 3 (next-gen combo) |
| Amycretin | Phase 2 |

**Oral Wegovy:** "Wegovy-in-a-pill" could be major catalyst.

---

## Restructuring

| Action | Detail |
|--------|--------|
| Job cuts | **9,000 positions** globally |
| Savings target | DKK 8B annually by end 2026 |
| Reason | Growth slowdown, efficiency |

---

## Price cuts

**70% US price reduction** announced to improve access and counter compounding pharmacies.

---

## Investment case

**Bull:**
- GLP-1 market leader
- Oral Wegovy launch 2026
- 68% international market share
- CagriSema pipeline

**Bear:**
- Lilly gaining share (58% US)
- Growth decelerating sharply
- Stock down 50% — still catching falling knife?
- Price pressure intensifying

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | NVO |
| Exchange | NYSE |
| Revenue | ~$33B (semaglutide) |
| Focus | GLP-1, diabetes, obesity |

---

## Related

- [[Eli Lilly]] — main competitor
- [[Amgen]] — MariTide challenger
- [[Biopharma]] — sector

---

## Sources

- [CNBC: Q3 earnings](https://www.cnbc.com/2025/11/05/wegovy-ozempic-maker-novo-nordisk-q3-earnings.html)
- [CNBC: Oral GLP-1 approval](https://www.cnbc.com/2025/12/23/wegovy-maker-novo-nordisk-shares-surge-after-glp-1-pill-approval.html)
- [BioPharma Dive](https://www.biopharmadive.com/news/novo-nordisk-3q-earnings-obesity-drug-sales-outlook/804727/)

*Created 2026-01-09*
